Providing Smarter Solutions For a
Healthier Life

Our core competencies lie in the research and development, manufacturing, commercialisation and marketing of over 300 generic drugs. These include popular brands such as Omesec, Prelica, CHAMPS®, FLAVETTES®, PROVITON® and Uphamol, which are well-recognised and accepted by consumers globally. We have also diversified into the biosimilars space, with technology and commercialisation collaborations with valuable international partners.

Results in Numbers

How we're making a difference in the healthcare ecosystem

More than

1500

People

More than

400

Products

Outlook

“As we exit the pandemic and return to social normalcy, people have better recognition of importance of healthcare and pharmaceuticals. We are optimistic that 2023 and beyond will see our business growing into new and more innovative opportunities that better serve the health and wellbeing of our communities.”
Leonard Ariff Abdul Shatar
Group Managing Director

Generics Explained.

Generic medicines are required to be the same as branded medicines in terms of dosage, safety, effectiveness, strength, stability and quality. Generic medicines therefore have the same effects, risks and benefits as their branded counterparts. Differences are mainly cosmetic, in the shape, size, colour and packaging, none of which affects how the medicines work. Generic medicines cost a fraction of branded ones, making it more beneficial to national healthcare systems that make medical treatment more accessible.

Read more about generic medicine programmes in the USA, UK, Singapore and Malaysia.

Duopharma Biotech Sponsors the UNGCMYB GO ESG ASEAN 2022 Summit.

The United Nations Global Compact Network Malaysia & Brunei (UNGCMYB) has organised GO ESG ASEAN 2022 Summit from 23-24 November 2022, and Duopharma Biotech was the Silver Sponsor for this event. Themed “Data Driven Sustainability: Accelerating ESG Impact for ASEAN”, the summit aims to facilitate pathway towards well managed Environmental, Social & Governance (“ESG”) data to enable more effective, timely and evidence-based decision making; while enhancing risk assessments in ESG investments evaluations, policy developments and resource allocations.

OUR BUSINESS AREAS

Excellence in Services

We are leaders in providing consultancy services with a set of cutting-edge technologies and a team of experienced and renowned professionals. These are some options that you can hire.

Audit & Assurance

Lorem ipsum dolor sit amet consectetur adipiscing elit.

Financial Advisory

Lorem ipsum dolor sit amet consectetur adipiscing elit.

Analytics and M&A

Lorem ipsum dolor sit amet consectetur adipiscing elit.

Middle Marketing

Lorem ipsum dolor sit amet consectetur adipiscing elit.

Legal Consulting

Lorem ipsum dolor sit amet consectetur adipiscing elit.

Regulatory Risk

Lorem ipsum dolor sit amet consectetur adipiscing elit.

Updates